This page shows the details of why an item matched the keywords from your search.
I am a pulmonary & critical care physician-scientist whose interests focus on the intersection between clinical risk-prediction models and genomic markers to improve pulmonary fibrosis outcomes.
Pulmonary fibrosis is a destructive interstitial lung disease characterized by profound scarring. In severe pulmonary fibrosis, death generally ensues within three to five years. Recent genomic advances have identified factors that influence heterogeneity and prognosis in pulmonary fibrosis. However, healthcare disparities and the exclusion of major racial groups from these genetic studies limits the generalizability of their findings. My work leverages advanced statistical techniques to improve the delivery of high-quality care in patients with fibrotic lung diseases. Much of my research is aimed at identifying improved practical strategies to optimize pharmacotherapy in patients with pulmonary fibrosis.
The main thrust of my work is currently on utilizing genetic data from diverse races to improve clinical decision-making and outcomes for all patients with pulmonary fibrosis.